A Survey of the Structures of US FDA Approved Combination Drugs

被引:209
作者
Das, Pradipta [1 ]
Delost, Michael D. [1 ]
Qureshi, Munaum H. [1 ]
Smith, David T. [1 ]
Njardarson, Jon T. [1 ]
机构
[1] Univ Arizona, Dept Chem & Biochem, 1306 East Univ Blvd, Tucson, AZ 85721 USA
基金
美国国家科学基金会;
关键词
PHARMACOKINETIC PROPERTIES; BACTERICIDAL AGENT; ANTIVIRAL ACTIVITY; CANCER-THERAPY; MANAGEMENT; HISTORY; HYDROCHLOROTHIAZIDE; MECHANISMS; INHIBITOR; DISCOVERY;
D O I
10.1021/acs.jmedchem.8b01610
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Combination drugs are an important class of US FDA approved pharmaceuticals. These drugs have been on a continuous growth trajectory since the first combination drugs were approved in the 1940s. In this Perspective, we report the first comprehensive compilation and analysis of US FDA approved combination drugs, from the first approval in 1943 through 2018. Our database contains 419 combination drugs, which are represented by 328 unique small molecule structures. Breakdown of these drugs according to disease category, structure, combination composition, and year of approval is presented as well as the top 24 most commonly used small molecule combination drug components. For frequently used small molecule components, we present "relationship diagrams" to aid in the visualization of the many drug combinations these structures are part of. The main body contains 10 disease-focused sections wherein every small molecule component utilized as part of a combination for each disease category is displayed.
引用
收藏
页码:4265 / 4311
页数:47
相关论文
共 156 条
  • [1] Myelodysplastic syndromes
    Ades, Lionel
    Itzykson, Raphael
    Fenaux, Pierre
    [J]. LANCET, 2014, 383 (9936) : 2239 - 2252
  • [2] Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases
    Alagha, Khuder
    Palot, Alain
    Sofalvi, Tunde
    Pahus, Laurie
    Gouitaa, Marion
    Tummino, Celine
    Martinez, Stephanie
    Charpin, Denis
    Bourdin, Arnaud
    Chanez, Pascal
    [J]. THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2014, 5 (02) : 85 - 98
  • [3] ALBANO E, 1985, MOL PHARMACOL, V28, P306
  • [4] Quinupristin/dalfopristin: A therapeutic review
    Allington, DR
    Rivey, MP
    [J]. CLINICAL THERAPEUTICS, 2001, 23 (01) : 24 - +
  • [5] [Anonymous], 2017, MED LETT DRUGS THER, V59, P182
  • [6] [Anonymous], 2013, P T
  • [7] Recent advances in migraine therapy
    Antonaci, Fabio
    Ghiotto, Natascia
    Wu, Shizheng
    Pucci, Ennio
    Costa, Alfredo
    [J]. SPRINGERPLUS, 2016, 5
  • [8] Armand Jean-Pierre, 2007, Ther Clin Risk Manag, V3, P213
  • [9] Metformin: historical overview
    Bailey, Clifford J.
    [J]. DIABETOLOGIA, 2017, 60 (09) : 1566 - 1576
  • [10] Characteristics of compounds that cross the blood-brain barrier
    Banks, William A.
    [J]. BMC NEUROLOGY, 2009, 9